TY - JOUR
T1 - HIV-associated cognitive impairment before and after the advent of combination therapy
AU - Sacktor, Ned
AU - McDermott, Michael P.
AU - Marder, Karen
AU - Schifitto, Giovanni
AU - Selnes, Ola A.
AU - McArthur, Justin C.
AU - Stern, Yaakov
AU - Albert, Steve
AU - Palumbo, Donna
AU - Kieburtz, Karl
AU - De Marcaida, Joy A.
AU - Cohen, Bruce
AU - Epstein, Leon
PY - 2002
Y1 - 2002
N2 - The objective of this study was to describe the occurrence of HIV dementia and neuropsychological testing abnormalities in a new cohort of HIV-seropositive individuals at high risk for HIV dementia and to compare these results to a cohort before the advent of highly active antiretroviral therapy (HAART). HAART has been associated with improvements in cognitive performance in some HIV-infected patients. However, it is uncertain whether HAART has changed the frequency of specific neurocognitive abnormalities. Baseline data from 272 HIV-seropositive subjects in the Dana cohort recruited from January, 1994, to December, 1995, and 251 HIV-seropositive subjects in the Northeastern AIDS Dementia Consortium (NEAD) cohort recruited from April, 1998, to August, 1999, were compared. Participants in both cohorts received nearly identical assessments. After adjusting for differences in age, education, gender, race, and CD4 count between the two cohorts, there were no differences in the occurrence of HIV dementia or abnormalities either 1 SD or 2 SDs below established norms for any of the neuropsychological tests. Even though HAART has reduced the incidence of HIV dementia, HIV-associated cognitive impairment continues to be a major clinical problem among individuals with advanced infection.
AB - The objective of this study was to describe the occurrence of HIV dementia and neuropsychological testing abnormalities in a new cohort of HIV-seropositive individuals at high risk for HIV dementia and to compare these results to a cohort before the advent of highly active antiretroviral therapy (HAART). HAART has been associated with improvements in cognitive performance in some HIV-infected patients. However, it is uncertain whether HAART has changed the frequency of specific neurocognitive abnormalities. Baseline data from 272 HIV-seropositive subjects in the Dana cohort recruited from January, 1994, to December, 1995, and 251 HIV-seropositive subjects in the Northeastern AIDS Dementia Consortium (NEAD) cohort recruited from April, 1998, to August, 1999, were compared. Participants in both cohorts received nearly identical assessments. After adjusting for differences in age, education, gender, race, and CD4 count between the two cohorts, there were no differences in the occurrence of HIV dementia or abnormalities either 1 SD or 2 SDs below established norms for any of the neuropsychological tests. Even though HAART has reduced the incidence of HIV dementia, HIV-associated cognitive impairment continues to be a major clinical problem among individuals with advanced infection.
KW - Behavior
KW - Cognitive disorders
KW - Dementia
KW - Infections
KW - Neuropsychology
UR - http://www.scopus.com/inward/record.url?scp=0036091705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036091705&partnerID=8YFLogxK
U2 - 10.1080/13550280290049615
DO - 10.1080/13550280290049615
M3 - Article
C2 - 11935465
AN - SCOPUS:0036091705
SN - 1355-0284
VL - 8
SP - 136
EP - 142
JO - Journal of neurovirology
JF - Journal of neurovirology
IS - 2
ER -